Concepedia

Meifeng Tu

MT

22

Publications

2.2K

Citations

18

H-Index

2004

Active since

Affiliations

Peking University Cancer Hospital(Current)

Peking University

The University of Texas MD Anderson Cancer Center

Odense University Hospital

University Hospital of Basel

Meifeng Tu is an author at Peking University Cancer Hospital specializing in medicine, immunology, and pathology.

Top concepts

Publications per year

2004–2021

22

Publications

22

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Shimin Hu, Zijun Y. Xu‐Monette, Alexandar Tzankov et al. · Blood · 2013 · 671 citations · Full text

A safe and potent anti-CD19 CAR T cell therapy

Zhitao Ying, Xue F. Huang, Xiaoyu Xiang et al. · Nature Medicine · 2019 · 435 citations · Full text

, , +2

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Li Yu, Meifeng Tu, Jörge E. Cortes et al. · Blood · 2017 · 171 citations · Full text

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma

Zhitao Ying, Ting He, Xiaopei Wang et al. · Molecular Therapy — Oncolytics · 2019 · 163 citations · Full text

Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin

Lijuan Deng, Yuqin Song, Ken H. Young et al. · Oncotarget · 2015 · 95 citations · Full text

Rows per page

1–5 of 22